

VOTE FOR THE RADOFF-JEC GROUP'S NOMINEES TODAY TO PREVENT FURTHER VALUE DESTRUCTION AT SEER (NASDAQ: SEER)

CORRECTING SEER AND OMID FAROKHZAD'S MISLEADING STATEMENTS

Don't be misled by Seer's omissions and spin tactics. Before you vote, arm yourself with the facts.

Seer's Reasons for Rejecting Our Premium Bids¹

"[T]he Board carefully reviewed the Revised Proposal in consultation with its independent financial and legal advisors. Following a thorough analysis, the Board concluded that the Revised Proposal significantly undervalues Seer."

"[T]he Second Unsolicited Proposal fails to reflect the value of Seer's Proteograph Product Suite platform, as well as Seer's technology leadership, adoption momentum and standalone growth prospects."

The Reality

The Board never spoke to us.

Dr. Farokhzad has incinerated more than \$1 billion of investor capital across at least five separate companies. At Seer, Dr. Farokhzad has overseen a -97.0% share price decline, non-existent revenue growth and ~\$311 million cash burn.

Taken together, how can stockholders believe the potential value of Seer as a standalone enterprise under Dr. Farokhzad will be superior to the \$2.40 per share in cash and CVR that we are offering?

Dr. Farokhzad and the other directors have been granted stock options at exercise prices well below our \$2.40 per share cash offer, and received restricted stock units based on a share price below our offer as well.

Seer is a microcap business that is projected to grow revenue by just 3% this year after burning nearly \$16 million in cash in the most recent quarter.

The Company's first quarter results were so disappointing that its stock – which had risen following our initial acquisition proposal – fell to below the unaffected share price in the days after the earnings report.²

¹ The Company's April 27, 2026 press release and 2026 proxy statement.

² FactSet. On April 10, 2026, the trading day immediately prior to the Radoff-JEC Group's submission of its initial non-binding proposal to acquire the Company, Seer's share price closed at \$1.69. One week after the Company reported Q1 2026 earnings on May 13, 2026, Seer's share price closed at \$1.68 on May 20, 2026.

Dr. Farokhzad's False Narrative³

"[Dr. Farokhzad has] deep expertise in biotechnology, nanotechnology, drug delivery, and building innovative life sciences platforms."

"Seer was founded by visionaries who, collectively, remain the Company's largest stockholders by a significant margin."

"We believe that electing any of Radoff and Torok's nominees would diminish the overall quality of Seer's Board."

The Reality

Dr. Farokhzad conveniently omits the fact that he has destroyed more than \$1 billion in investor capital across Seer, BIND Therapeutics, Inc. (formerly NASDAQ: BIND), Selecta Biosciences, Inc. (formerly NASDAQ: SELB), Tarveda Therapeutics, Inc. and Senti Biosciences, Inc. (n/k/a Senti Biosciences Holdings, Inc.; NASDAQ: SNTI).⁴ In each of these cases, the company either went bankrupt or the share price declined more than 90% – or, in some cases, both.

The failures at Seer and its -97.0% share price decline are consistent with Dr. Farokhzad's track record across multiple companies.

Seer's Board unilaterally adopted a poison pill to prevent stockholders from owning more than 4.9% of the Company.

Dr. Farokhzad himself has sold over \$103 million of Seer stock since the Company's IPO – that's more stock than the Company's current entire market capitalization.

Seer's independent directors have never purchased a single share of the Company.

Seer's Board is full of Dr. Farokhzad's connections – electing our nominees would inject much-needed independence and quality.

Targeted directors Dipchand Nishar and Terrance McGuire were involved with a SPAC that was founded by Dr. Farokhzad and combined with Senti Biosciences, Inc., as was director Robert Langer, Sc.D., who has had a front-row seat to each of Dr. Farokhzad's five spectacular failures.

Director Isaac Ro is also a board member of PrognomiQ, where Dr. Farokhzad is board chair and of which Seer owns approximately 20%.

³ The Company's June 3, 2026 DEF14A filing.

⁴ Respective company filings and announcements.